vs
Prestige Consumer Healthcare Inc.（PBH）与Ranger Energy Services, Inc.（RNGR）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是Ranger Energy Services, Inc.的2.0倍（$283.4M vs $142.2M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 2.3%，领先14.2%），Ranger Energy Services, Inc.同比增速更快（-0.6% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $17.1M），过去两年Ranger Energy Services, Inc.的营收复合增速更高（1.9% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
Ranger Energy Services是北美领先的陆上油田服务提供商，为上游油气运营商提供完井、修井、钻机作业及产能优化等全套解决方案，业务主要覆盖美国本土的页岩和致密资源开采作业区。
PBH vs RNGR — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $142.2M |
| 净利润 | $46.7M | $3.2M |
| 毛利率 | 55.5% | — |
| 营业利润率 | 29.1% | 2.3% |
| 净利率 | 16.5% | 2.3% |
| 营收同比 | -2.4% | -0.6% |
| 净利润同比 | -23.5% | -44.8% |
| 每股收益（稀释后） | $0.97 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $283.4M | $142.2M | ||
| Q3 25 | $274.1M | $128.9M | ||
| Q2 25 | $249.5M | $140.6M | ||
| Q1 25 | $296.5M | $135.2M | ||
| Q4 24 | $290.3M | $143.1M | ||
| Q3 24 | $283.8M | $153.0M | ||
| Q2 24 | $267.1M | $138.1M | ||
| Q1 24 | $277.0M | $136.9M |
| Q4 25 | $46.7M | $3.2M | ||
| Q3 25 | $42.2M | $1.2M | ||
| Q2 25 | $47.5M | $7.3M | ||
| Q1 25 | $50.1M | $600.0K | ||
| Q4 24 | $61.0M | $5.8M | ||
| Q3 24 | $54.4M | $8.7M | ||
| Q2 24 | $49.1M | $4.7M | ||
| Q1 24 | $49.5M | $-800.0K |
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 55.5% | — | ||
| Q2 24 | 54.7% | — | ||
| Q1 24 | 54.8% | — |
| Q4 25 | 29.1% | 2.3% | ||
| Q3 25 | 29.1% | 2.0% | ||
| Q2 25 | 28.8% | 6.1% | ||
| Q1 25 | 29.8% | 0.7% | ||
| Q4 24 | 31.7% | 6.2% | ||
| Q3 24 | 29.7% | 8.4% | ||
| Q2 24 | 27.0% | 5.3% | ||
| Q1 24 | 29.7% | -0.4% |
| Q4 25 | 16.5% | 2.3% | ||
| Q3 25 | 15.4% | 0.9% | ||
| Q2 25 | 19.0% | 5.2% | ||
| Q1 25 | 16.9% | 0.4% | ||
| Q4 24 | 21.0% | 4.1% | ||
| Q3 24 | 19.2% | 5.7% | ||
| Q2 24 | 18.4% | 3.4% | ||
| Q1 24 | 17.9% | -0.6% |
| Q4 25 | $0.97 | $0.14 | ||
| Q3 25 | $0.86 | $0.05 | ||
| Q2 25 | $0.95 | $0.32 | ||
| Q1 25 | $1.00 | $0.03 | ||
| Q4 24 | $1.22 | $0.24 | ||
| Q3 24 | $1.09 | $0.39 | ||
| Q2 24 | $0.98 | $0.21 | ||
| Q1 24 | $0.98 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $10.3M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $300.1M |
| 总资产 | $3.5B | $419.3M |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
| Q4 25 | $62.4M | $10.3M | ||
| Q3 25 | $119.1M | $45.2M | ||
| Q2 25 | $139.5M | $48.9M | ||
| Q1 25 | $97.9M | $40.3M | ||
| Q4 24 | $50.9M | $40.9M | ||
| Q3 24 | $51.5M | $14.8M | ||
| Q2 24 | $34.3M | $8.7M | ||
| Q1 24 | $46.5M | $11.1M |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | $0 | ||
| Q3 24 | $1.1B | $0 | ||
| Q2 24 | $1.1B | $0 | ||
| Q1 24 | $1.1B | $0 |
| Q4 25 | $1.8B | $300.1M | ||
| Q3 25 | $1.8B | $270.0M | ||
| Q2 25 | $1.9B | $276.9M | ||
| Q1 25 | $1.8B | $272.6M | ||
| Q4 24 | $1.8B | $273.8M | ||
| Q3 24 | $1.7B | $267.6M | ||
| Q2 24 | $1.7B | $260.5M | ||
| Q1 24 | $1.7B | $261.7M |
| Q4 25 | $3.5B | $419.3M | ||
| Q3 25 | $3.4B | $372.8M | ||
| Q2 25 | $3.4B | $381.7M | ||
| Q1 25 | $3.4B | $376.5M | ||
| Q4 24 | $3.3B | $381.6M | ||
| Q3 24 | $3.3B | $373.9M | ||
| Q2 24 | $3.3B | $359.6M | ||
| Q1 24 | $3.3B | $355.5M |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | 0.00× | ||
| Q3 24 | 0.61× | 0.00× | ||
| Q2 24 | 0.65× | 0.00× | ||
| Q1 24 | 0.68× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $24.1M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $17.1M |
| 自由现金流率自由现金流/营收 | 26.6% | 12.0% |
| 资本支出强度资本支出/营收 | 1.1% | 4.9% |
| 现金转化率经营现金流/净利润 | 1.68× | 7.53× |
| 过去12个月自由现金流最近4个季度 | $267.2M | $42.9M |
8季度趋势，按日历期对齐
| Q4 25 | $78.3M | $24.1M | ||
| Q3 25 | $57.5M | $13.6M | ||
| Q2 25 | $79.0M | $20.7M | ||
| Q1 25 | $61.8M | $10.6M | ||
| Q4 24 | $65.1M | $32.7M | ||
| Q3 24 | $69.8M | $17.7M | ||
| Q2 24 | $54.8M | $22.1M | ||
| Q1 24 | $66.9M | $12.0M |
| Q4 25 | $75.3M | $17.1M | ||
| Q3 25 | $55.4M | $8.0M | ||
| Q2 25 | $78.2M | $14.4M | ||
| Q1 25 | $58.4M | $3.4M | ||
| Q4 24 | $63.5M | $27.3M | ||
| Q3 24 | $67.8M | $10.8M | ||
| Q2 24 | $53.6M | $6.8M | ||
| Q1 24 | $63.8M | $5.5M |
| Q4 25 | 26.6% | 12.0% | ||
| Q3 25 | 20.2% | 6.2% | ||
| Q2 25 | 31.3% | 10.2% | ||
| Q1 25 | 19.7% | 2.5% | ||
| Q4 24 | 21.9% | 19.1% | ||
| Q3 24 | 23.9% | 7.1% | ||
| Q2 24 | 20.1% | 4.9% | ||
| Q1 24 | 23.0% | 4.0% |
| Q4 25 | 1.1% | 4.9% | ||
| Q3 25 | 0.8% | 4.3% | ||
| Q2 25 | 0.3% | 4.5% | ||
| Q1 25 | 1.2% | 5.3% | ||
| Q4 24 | 0.5% | 3.8% | ||
| Q3 24 | 0.7% | 4.5% | ||
| Q2 24 | 0.4% | 11.1% | ||
| Q1 24 | 1.1% | 4.7% |
| Q4 25 | 1.68× | 7.53× | ||
| Q3 25 | 1.36× | 11.33× | ||
| Q2 25 | 1.66× | 2.84× | ||
| Q1 25 | 1.23× | 17.67× | ||
| Q4 24 | 1.07× | 5.64× | ||
| Q3 24 | 1.28× | 2.03× | ||
| Q2 24 | 1.12× | 4.70× | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
